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Summary
BACKGROUND: The overall burden of healthcare-associ-
ated infections (HAIs) remains high, even in high-income
countries. However, the current burden of HAI in Switzer-
land is unknown. Prevalence surveys have a long tradition
in the field of infection prevention and control for mea-
suring both HAI and antimicrobial use. The objective of
this survey was to test the point prevalence survey (PPS)
methodology of the European Centre for Disease Pre-
vention and Control (ECDC) in acute-care hospitals in
Switzerland.
METHODS: Two tertiary care hospitals and one sec-
ondary care hospital in central and western Switzerland
participated in the survey. Patients from all wards except
for emergency departments and psychiatric wards were
included. Data were collected on a single day for every
ward with a maximum time frame of 2 weeks for com-
pleting data collection. Methodology and definitions were
based on the most recent ECDC PPS protocol.
RESULTS: Data on a total of 2421 patients were analysed.
One hundred thirty-six patients had 153 HAIs, correspond-
ing to a prevalence of 5.6% (95% confidence interval [CI]
4.7–6.5%). Rapidly fatal McCabe score, hospitalisation in
the intensive care unit (ICU), and having a medical de-
vice in place were independent risk factors for HAI. Low-
er respiratory tract infection was the most frequent HAI
type (24.8%), followed by surgical site infection (22.2%),
bloodstream infection (17.0%) and urinary tract infection
(13.7%). The highest HAI prevalence (26.2%) was ob-
served in the ICU. In total, 60.8% of all HAIs were mi-
crobiologically confirmed. The most common microorgan-
ism was Escherichia coli (21.1%). Six hundred sixty-nine
patients (27.6%, 95% CI 25.9–29.4%) received 893 an-
timicrobials for 705 indications. Community-acquired in-
fections (39.0%) were the most common indication for an-
timicrobial use and amoxicillin-clavulanate was the most
commonly prescribed antimicrobial (18.4%).
CONCLUSIONS: HAI prevalence and antimicrobial use
in this survey were similar to findings of the past ECDC
PPS. The ECDC methodology proved applicable to Swiss
acute-care hospitals.
Key words: point prevalence survey, Switzerland, multi-
centre, healthcare-associated infection, antibiotic use
Introduction
The overall burden of healthcare-associated infections
(HAIs) remains high, although efforts in infection preven-
tion and control have resulted in HAI reduction in some
countries [1]. According to the World Health Organization
(WHO), 7% of patients in developed countries and 16%
in developing countries have at least one HAI at any one
time during hospitalisation, with a mortality rate estimated
at 10% [2].
Prevalence surveys have a long tradition in the field of in-
fection prevention and control [3]. In the early 1970s, the
SENIC (study on the efficacy of nosocomial infection con-
trol) study in the United States used repeated point preva-
lence surveys (PPSs) to demonstrate the effect of infection
prevention and control units in US acute-care hospitals [4].
As early as 1981, a group of WHO experts recommended
use of national PPSs as a tool to estimate the global bur-
den of HAI [5]. Although the response was below expecta-
tion at that time, a growing number of countries conducted
national surveys in the following years. The last national
prevalence surveys in Switzerland date back to 2003 and
2004 [6, 7]. HAI prevalence surveys have fallen into dis-
use until recently, when the US Centers for Disease Con-
trol and Prevention (CDC) and the European Centre for
Disease Prevention and Control (ECDC) performed large-
scale national (CDC PPS) and multinational (ECDC PPS)
surveys to set HAI benchmarks [8, 9].
Although some Swiss hospitals continued doing periodical
local prevalence studies after 2004, the global burden of
HAI in Switzerland today is unknown, because current
data are lacking and the former prevalence surveys did
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not use the “point” methodology, but rather the “period”
methodology, which makes benchmarking with other sur-
veys impossible [3]. In January 2013, the Swiss Federal
Council approved its “Health 2020” plan, which set public
health priorities for the coming years in Switzerland, and
defined the reduction of HAIs as a first-order measure.
For this purpose, the national strategy “Strategie NOSO”
was established [10]. Within this strategy, measuring HAI
is a priority. The objective of this survey was to pilot
the ECDC PPS methodology in acute-care hospitals in
Switzerland ahead of a national PPS.
Materials and methods
A small number of acute-care hospitals in Switzerland
were asked to participate in this multicentre cross-sectional
study. Three acute-care hospitals accepted the invitation,
among them two university hospitals (1954 and 957 beds,
respectively) and one large regional hospital (825 beds).
All patients (including children and neonates) were eligible
to be included if admitted to the ward before or at 8 a.m.
and not discharged (either home or to a different ward) dur-
ing the day of the survey. All wards, regardless of special-
ty, were eligible. Patients staying in the emergency room
for more than 24 hours and patients hospitalised in psy-
chiatry were excluded. Long-term rehabilitation and other
long-term care facilities were included in the survey if such
wards were an integral part of an otherwise acute-care hos-
pital. Data were collected in a single day for every ward,
but a maximum time frame of 2 weeks was accepted to
complete hospital-wide data collection.
Methodology and definitions were based on the most re-
cent ECDC PPS protocol, but without hospital indicator
data [11–13]. Indicator data from only three hospitals
would not have been informative. An infection was con-
sidered active when signs and symptoms of the infection
were present on the survey date or signs and symptoms
were present in the past and the patient was (still) receiving
treatment for that infection on the day of survey. In addi-
tion, one of the following conditions had to be fulfilled: (1)
the onset of symptoms was on Day 3 or later (day of admis-
sion = Day 1) of the current admission or the patient pre-
sents with an infection but has been readmitted <48 hours
after a previous admission to an acute care hospital; (2)
the patient was admitted (or developed symptoms within
2 days) with an infection that met the case definition of
an active surgical site infection, i.e. the infection occurred
within 30 days after the procedure (or in the case of surgery
involving an implant, was a deep or organ/space surgical
site infection that developed within 90 days of the opera-
tion) and the patient either had symptoms that met the case
definition and/or was on antimicrobial treatment for that
infection; (3) the patient had been admitted (or developed
symptoms within 2 days) with Clostridium difficile infec-
tion <28 days after a previous discharge from an acute care
hospital; (4) an invasive device was placed on Day 1 or
Day 2, resulting in an HAI before Day 3.
Investigators were trained on the protocol by the Swiss
PPS coordination centre in Geneva. Spring and autumn
were defined as steady-state periods with normal hospital
activity and without seasonal outbreaks. Therefore, hospi-
tals were asked to collect data either from April to June
2016 or from October to December of the same year.
Data from two hospitals were reported directly to the Swiss
PPS coordination centre. The third hospital collected data
within an electronic database later to be used for the na-
tional PPS. All patient data were anonymised. Rapidly fa-
tal McCabe score (expected fatal outcome within 1 year)
[14], age groups (0–17, 18–40, 41–60, 61–80, >80 years),
hospitalisation in the intensive care unit (ICU) at survey,
having a medical device (peripheral venous catheter, cen-
tral venous catheter, urinary catheter, endotracheal tube) in
place during survey, and having undergone NHSN (nation-
al healthcare survey network) surgery before survey, were
tested in a univariable logistic regression analysis. Vari-
ables with a significance level of p = 0.2 were tested in
a multivariable model. Observations were clustered on the
hospital level, and a two-sided p-value of 0.05 was consid-
ered significant. Data analysis was performed using STA-
TA version 13 (STATA Corporation).
Results
Two tertiary care centres and one secondary care centre
in central and western Switzerland with >650 beds each
agreed to participate in the pilot PPS. Two hospitals were
university-affiliated, and one hospital was a cantonal hos-
pital. One hospital performed the survey in May 2016, the
two other hospitals in October 2016. The three hospitals
collected data on a total of 2421 patients. Table 1 sum-
marises the patients’ characteristics, including use of med-
ical devices, and ward specialty for all patients, stratified
by patients with HAI, and patients receiving one or more
antimicrobials on the day of survey. Median (interquartile
range) length of stay, defined as days between hospital ad-
mission and day of survey, was 5 (2–12) days.
One hundred thirty-six patients suffered from 153 HAIs,
corresponding to a prevalence of 5.6% (95% confidence
interval [CI] 4.7–6.5%). Rapidly fatal McCabe score (odds
ratio [OR] 2.02, 95% CI 1.58–2.58), hospitalisation in in-
tensive care (OR 3.80, 95% CI 2.58–5.61), and having a
medical device in place (OR 4.43, 95% CI 3.49–5.63) were
independent risk factors for HAI in the multivariable mod-
el (table 2). Lower respiratory tract infection was the most
frequent HAI type (24.8%), followed by surgical site infec-
tion (22.2%), bloodstream infection (17.0%), and urinary
tract infection (13.7%) (fig. 1). The highest HAI preva-
lence (26.2%) was observed in the ICU (fig. 2). HAI preva-
lences in other ward types were similar (5.5–8.3%), except
in gynaecology and obstetrics, where no HAIs were iden-
tified (fig. 2). The highest HAI prevalence was observed
in the age groups 41–60 years (6.3%, 95% CI 4.1–8.5%)
and 61–80 years (6.6%, 95% CI 5.0–8.3%). However, age
groups did not correlate with likelihood of having HAI
(table 2). In total, 133 microorganisms were identified in
93 of the 153 HAIs (60.8%). The most common microor-
ganisms of the 133 were Escherichia coli (21.1%), fol-
lowed by Enterococcus faecium (9.8%), Pseudomonas
aeruginosa (9.0%), Klebsiella pneumoniae (8.3%), Can-
dida albicans (6.0%), Staphylococcus epidermidis (6.0%),
Clostridium difficile (3.8%) and Enterobacter cloacae
(2.3%). Figure 3 summarises the distribution of the dif-
ferent groups of microorganisms. The proportions of me-
thicillin-resistant Staphylococcus aureus, vancomycin-re-
sistant enterococci, and third generation cephalosporin-re-
sistant Enterobacteriaceae were 16.7% (2/12), 5.3% (1/
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19) and 27.5% (14/51), respectively. Neither carbapenem-
resistant Enterobacteriaceae nor carbapenem-resistant
Pseudomonas aeruginosa were identified.
Six hundred sixty-nine patients (27.6%, 95% CI
25.9–29.4%) received 893 antimicrobials for 705 indica-
tions on the day of the survey (table 3). The highest propor-
tion of antimicrobial use was identified in the ICU (62.0%,
95% CI 46.6–77.2%), followed by surgery (38.3%, 95%
CI 34.6–42.0%) and mixed wards (37.0%, 95% CI
29.3–44.6%). A single antimicrobial was applied for 548
indications (77.7%, 95% CI 47.7–80.8%). Two or more
concurrent antimicrobials were applied for 157 (22.3%,
95% CI 19.2–25.5%) indications. Community-acquired in-
fections (39.0%) were the most common indication for
antimicrobial use, followed by nosocomial infections
(20.6%), surgical prophylaxis (17.7%), medical prophylax-
is (16.2%) and other indications (6.4%). Antimicrobials
were given for more than one postoperative day in more
than half (52.8%) of surgical prophylaxis administrations.
Amoxicillin/clavulanate was the most commonly pre-
scribed antimicrobial (18.4%), followed by ceftriaxone
(8.5%), sulfamethoxazole-trimethoprim (8.5%), cefurox-
ime (8.3%) and piperacillin-tazobactam (8.2%). The most
common antimicrobial groups were penicillin combina-
tions (25.9%), followed by third-generation
Figure 1: Distribution of healthcare-associated infections (n = 153)
– multicentre point prevalence survey, Switzerland 2016.BSI =
bloodstream infection; EENT = ear/eye/nose/throat infection; GI =
gastrointestinal infection; LRTI = lower respiratory tract infection;
NEO = neonatal infection; OTH = other infection; SSI = surgical
site infection; SYS = systemic infection; UTI = urinary tract infec-
tion
Table 1: Characteristics of patients – multicentre point prevalence survey, Switzerland 2016.
All patients Patients with HAI Patients on AM
Patients, N 2421 136 669
Patient characteristics
Age (years), median (IQR) 68 (48–80) 68.5 (56–79.5) 66 (48–76)
McCabe score*, % (95% CI)
No fatal disease 75.3 (73.5–77.0) 61.2 (52.5–69.3) 72.9 (69.3–76.2)
Ultimately fatal disease 21.3 (17.9–23.0) 31.0 (23.5–40.0) 22.5 (19.4–25.9)
Rapidly fatal disease 3.4 (2.7–4.2) 7.8 (4.2–13.9) 4.6 (3.2–6.5)
Exposure
Surgery†, % (95% CI) 30.0 (28.0–32.0) 43.4 (35–52) 44.2 (40.5–48.0)
Central venous catheter‡, % (95% CI) 12.0 (10.4–13.8) 38.5 (30.2–40.8) 27.2 (34.0–30.6)
Peripheral venous catheter‡, % (95%CI) 43.4 (41.4–45.4) 55.9 (47.5–64.3) 66.7 (63.3–70.4)
Urinary catheter‡, % (95% CI) 18.0 (16.6–19.7) 39.3 (30.9–47.6) 30.7 (27.3–34.3)
Mechanical ventilation‡, % (95% CI) 2.1 (1.6–2.8) 6.6 (2.4–10.8) 4.2 (2.9–6.0)
Length of stay§, median (IQR) 5 (2–12) 12 (5–21.5) 4 (2 –9)
Clinical settings
Geriatrics, % (95% CI) 10.5 (9.4–11.8) 11.8 (7.3–18.4) 5.2 (3.7–7.2)
Gynaecology, % (95% CI) 1.8 (1.3–2.4) 0.0 0.9 (0.4–2)
Obstetrics, % (95% CI) 6.5 (5.6–7.5) 0.0 2.9 (1.7–4.2)
Intensive care, % (95% CI) 1.7 (1.3–2.3) 8 (4.5–14.1) 3.9 (2.7–5.7)
Long-term care, % (95% CI) 8.7 (7.9–10.2) 5.9 (2.9–11.4) 2.4 (1.5–3.9)
Medicine, % (95% CI) 24.6 (22.9–26.3) 24.3 (17.7–32.3) 30.2 (26.8–33.8)
Mixed¶, % (95% CI) 6.5 (5.6–7.5) 9.6 (5.6–15.9) 8.7 (6.8–11.1)
Paediatrics, % (95% CI) 4.5 (3.7–5.4) 4.4 (2.0–10.0) 5.1 (3.7–7.0)
Rehabilitation, % (95% CI) 7.4 (6.4–8.5) 8 (4.5–14.1) 2.7 (1.7–4.2)
Surgery, % (95% CI) 27.6 (25.8–29.4) 23.5 (21.6–25.6) 38.3 (34.6–42.0)
AM = antimicrobial; CI = confidence interval; HAI = healthcare-associated infection; IQR = interquartile range * 54 missing values † Yes/no in the hospitalisation before survey ‡
Yes/no on the day of survey § Days before and including the day of the prevalence survey ¶ Wards with less than 80% of patients belonging to one specialty
Table 2: Uni- and multivariable risk factor analysis – multicentre point prevalence survey, Switzerland 2016.
Univariable analysis Multivariable analysisVariables
OR (95% CI) p-value OR (95% CI) p-value
Rapidly fatal McCabe score 2.51 (2.20–2.87) <0.001 2.02 (1.58–2.58) <0.001
Age group* 1.11 (0.93–1.32) 0.265
Intensive care unit 6.40 (4.63–8.83) <0.001 3.80 (2.58–5.61) <0.001
Medical device† 5.08 (4.45–5.81) <0.001 4.43 (3.49–5.63) <0.001
NHSN surgery‡ 1.77 (0.89–3.54) 0.106 1.41 (0.75–2.67) 0.288
CI = confidence interval; OR = odds ratio * Age groups: 0–17 years, 18–40 years, 41–60 years, 61–80 years, >80 years † Peripheral venous catheter, central venous catheter,
urinary catheter, endotracheal tube – on day of survey ‡ NHSN surgery: surgery according to the NHSN (national healthcare safety network) definitions before survey
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cephalosporins (8.7%), sulphonamide-trimethoprim com-
binations (8.5%), second-generation cephalosporins
(8.3%), and quinolones (7.5%). Figure 4 summarises the
Figure 2: Prevalence of healthcare-associated infections by ward
specialty – multicentre point prevalence survey, Switzerland
2016.GER = geriatrics; GO = Gynaecology; GOOBS = obstetrics;
ICU = intensive care unit; MED = medicine; PED = paediatrics;
REHA = rehabilitation; MIX = mixed unit; SUR = surgery
use of antimicrobial groups by ward specialty, revealing
beta-lactam antibiotics to be the largest group of antimicro-
bials prescribed in the majority of ward specialties.
Figure 3: Groups of microorganisms (n = 133) – multicentre point
prevalence survey, Switzerland 2016.anaerob = anaerobic bacte-
ria; enterobac = Enterobacteriaceae; fungi = fungi; gramnegbac =
Gram-negative bacilli (other than Enterobacteriaceae); gramneg-
coc = Gram-negative cocci; gramposcoc = Gram-positive cocci
Table 3: Antimicrobial use – multicentre point prevalence survey, Switzerland 2016.
Patients Indications for antimicrobial use
All
n
on AM
n
AM use
% (95% CI)
All
n
1 AM
% (95% CI)
2 AM
% (95% CI)
≥3 AM
% (95% CI)
Geriatrics 255 35 13.7 (9.5–18.0) 36 86.1 (74.2–98.0) 13.9 (2.0–25.8) 0.0
Gynaecology 43 6 14.0 (3.2–24.7) 6 100.0 0.0 0.0
Obstetrics 157 18 11.5 (6.4–16.5) 18 100.0 0.0 0.0
Intensive care 42 26 62.0 (46.6–77.2) 26 65.4 (45.8–85.0) 30.8 (11.8–49.8) 3.8 (0.0–11.8)
Long-term care 217 16 7.4 (3.9–10.9) 17 94.1 (81.6–100.0) 5.9 (0.0–18.4) 0.0
Medicine 595 202 33.9 (30.1–37.8) 221 74.7 (68.9–80.4) 20.8 (15.4–26.2) 4.5 (1.8–7.3)
Mixed* 157 58 37.0 (29.3–44.6) 61 72.1 (60.6–83.7) 24.6 (13.5–35.7) 3.3 (0.0–7.9)
Paediatrics 108 34 31.5 (22.6–40.4) 36 66.7 (50.5–82.8) 22.2 (8.0–36.5) 11.1 (0.3–21.9)
Rehabilitation 179 18 10.0 (5.6–14.5) 19 78.9 (58.8–99.1) 21.1 (0.9–41.2) 0.0
Surgery 668 256 38.3 (34.6–42.0) 265 80.0 (75.2–84.8) 16.6 (12.1–21.1) 3.4 (1.2–5.6)
Total 2421 669 27.6 (25.9–29.4) 705 77.7 (47.6–80.8) 18.6 (15.7–21.5) 3.7 (2.3–5.1)
AM = antimicrobial; CI = confidence interval * Wards with less than 80% of patients belonging to one specialty
Figure 4: Antimicrobial classes by ward specialty – multicentre point prevalence survey, Switzerland 2016.
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Discussion
This survey identified a pooled HAI prevalence of 5.6%
(95% CI 4.7–6.5%) in three large Swiss medical centres,
antimicrobial use in less than a third of inpatients, and En-
terobacteriaceae as the most common microorganisms iso-
lated from patients with HAIs.
The HAI prevalence was comparable to the prevalence of
6.0% overall, and the prevalence of 5.9% among hospitals
with more than 650 beds in the past ECDC PPS [9]. The
most recent PPS in Switzerland in 2004 identified a HAI
prevalence of 10.4% for the subset of large hospitals [7].
However, that survey measured HAI with the period preva-
lence methodology (which included HAI within a time
frame of 7 days before the survey day). This methodolo-
gy inflates the number of infections by a third (32%) com-
pared with the point prevalence methodology used here
for a case-mix of acute and long-term care [3]. Estimating
point prevalence from period prevalence data would result
in a HAI prevalence of 7.9% for large hospitals in 2004.
Compared with this rate from a decade ago, the identified
prevalence of the three participating hospitals in this sur-
vey was markedly lower. Similar to our findings, lower
respiratory tract infection was the most common HAI type
in the ECDC PPS (26%) [9], and the CDC PPS (26%) [1].
Also, surgical site infection was second in the CDC PPS
(22%), but third in the ECDC PPS (16%). Surgical site
infections were first in the past Swissnoso PPSs in 2003
(26%) and 2004 (29%) [6, 7]. This could have been an ef-
fect of the period methodology. However, recent prospec-
tive surgical site infection surveillance in Switzerland re-
vealed that 47% of all surgical site infection occur after
hospital discharge [15]. Thus, the true proportion of surgi-
cal site infection is most likely higher.
Interestingly, gastrointestinal infections were the third
most common HAI group in the CDC PPS (17%), with
Clostridium difficile causing 12% of all HAIs. Clostridium
difficile contributed to only 3.7% of all HAI in our survey,
but 27.8% of all gastrointestinal infections.
Antimicrobial use in the three large Swiss hospitals was
lower than in similar hospitals in Europe (35.3%) [9]. The
ECDC report did not stratify detailed antimicrobial use for
the different hospital sizes. However, the most common-
ly prescribed antimicrobial was amoxicillin-clavulanate in
both our survey and the ECDC PPS. Also, the other com-
mon antimicrobials were similar in both surveys, with cef-
triaxone, cefuroxime and piperacillin-tazobactam among
the first five. Sulfamethoxazole-trimethoprim ranked third
in our survey but was rarely used in the ECDC PPS. In-
terestingly, more than a half of the patients received surgi-
cal prophylaxis for more than 24 hours, which the WHO
recommends against. In our opinion, this finding should
trigger antimicrobial stewardship activities addressing best
practice in surgical prophylaxis.
This survey has limitations. First, data collection was done
by local infection prevention and control professionals and
not by the same study team. However, all participating data
collectors had experience with performing local PPSs in
the past, and were trained before data collection. Second,
the data are not representative for Switzerland because on-
ly three large hospitals were included. However, the data
are generalisable to other large hospitals. In addition, the
overall number of patients included in this survey is simi-
lar to the number from large hospitals included in the CDC
PPS (2214 patients). Third, data on antimicrobial resis-
tance are limited because only a small number of microor-
ganisms were tested as part of diagnosing HAI. This limits
the estimation of the resistance prevalence among the iso-
lated microorganisms.
Conclusion
This survey found similar numbers on HAI and antimicro-
bial use compared to the ECDC PPS. The ECDC method-
ology proved feasible in patients hospitalised in Swiss
acute-care hospitals.
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